Trabeculectomy With Ologen Collagen Implant vs Trabeculectomy With Provisc in Steroid Induced Glaucoma
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01912638|
Recruitment Status : Completed
First Posted : July 31, 2013
Last Update Posted : September 21, 2016
|Condition or disease||Intervention/treatment||Phase|
|Steroid Induced Glaucoma||Device: Ologen Collagen Matrix Drug: Provisc||Phase 1 Phase 2|
Steroid induced glaucoma is a well known and widely described disastrous clinical condition. However the subject of selection of most effective and safe treatment modality is still being discussed.
Sihota R et al reported that 26.5% cases required surgical treatment to control IOP. Unfortunately survival rate of successful blebs in 10 years after trabeculectomy varies from 40% to 60%. Anti-fibrotic agent MMC as adjunct to filtration surgery was used to prevent postoperative scarring that could compromise surgical success of trabeculectomy. Additional use of MMC in trabeculectomy leads to low final IOP but could be associated with such complications as cataract formation, intraocular toxicity, avascular filtering blebs, wound leakage, subsequent blebitis and endophthalmitis. Tissue-engineered biodegradable and biocompatible implant Ologen® Collagen Matrix may be used as an alternative to MMC. Ologen® is CE Mark and FDA approved artificial porcine extracellular matrix for modulating wound healing. Ologen® has been tested in animal models and has triple action:
- prevent the collapse of the subconjunctival space;
- guides the fibroblast to grow through the matrix pores thus preventing scar formation;
- may act as an aqueous reservoir (avoids post-op hyperfiltration and shallow anterior chamber).
The filtering blebs scoring was performed by using Moorfields Bleb Grading System and Visante anterior segment optical coherence tomography.
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||17 participants|
|Intervention Model:||Parallel Assignment|
|Masking:||None (Open Label)|
|Official Title:||Comparative Study of the Efficacy and Safety of Ologen Collagen Implant Versus Cohesive Viscoelastic in Trabeculectomy Performed for Steroid Induced Glaucoma|
|Study Start Date :||July 2012|
|Actual Primary Completion Date :||September 2016|
|Actual Study Completion Date :||September 2016|
Experimental: Implantation of Ologen in trabeculectomy
Ologen Collagen Matrix is implanted in primary limbal-based trabeculectomy. It should be placed on the top of the loosely-sutured scleral flap before suturing of the conjunctiva thus preventing the collapse of the subconjunctival space.
Device: Ologen Collagen Matrix
Ologen is a porous collagen-glycosaminoglycan matrix that decrease early postoperative scarring after penetrating anti-glaucomatous surgery by randomized collagen deposition and microcyst formation. Implantation of Ologen Collagen Matrix in trabeculectomy was performed.
Active Comparator: Provisc in trabeculectomy
Provisc is used in primary limbal-based trabeculectomy. At the end of the surgery cohesive viscoelastic (Provisc) is injected under the scleral flap to prevent early hypotony.
Provisc is an cohesive viscoelastic.
- Intraocular Pressure (IOP) [ Time Frame: 2 years ]
The absolute success was defined as an IOP less than 21 mmHg with no glaucoma medications.
Follow-up visits were and will arranged at 1 and 2 first weeks, then every month during first 6 months, then every 3 months during 2.5 years after surgery.
- Postoperative complications [ Time Frame: 2 years ]Complications were defined as follows: hypotony,shallow anterior chamber,serous or hemorrhagic choroidal detachment, hyphema,anterior chamber inflammation,persistent hypotonus maculopathy,corneal epithelial toxicity, "snuff" syndrome,blebitis or endophthalmitis,formation of Tenon's cyst.
- Corrected distance visual acuity (CDVA) [ Time Frame: 2 years ]
- Appearance of the filtering bleb (FB) [ Time Frame: 2 years ]
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01912638
|National Centre of Ophthalmology named after academician Zarifa Aliyeva|
|Baku, Azerbaijan, AZ1114|
|Study Director:||Elmar Kasimov, Professor||Director of National Centre of Ophthalmology|
|Principal Investigator:||Fidan Aghayeva, MD||Glaucoma consultant at National Centre of Ophthalmology|